Cell therapy

IB Communications’ CEO Michelle Boxall explains why there are two sides to the cell and gene therapy coin. Charles Dickens’ quote, “It was the best of times, it was the worst of times”, aptly describes the complexity surrounding CGT financing. With 2023’s financial outlook and predictions for the CGT market, there are two sides to […]

DDW’s Megan Thomas caught up with George White, General Manager, Product Management, Cell & Gene Therapy at Cytiva, to learn more about the company’s insight into the CGT market. Key challenges for cell and gene therapies In order for cell and gene (CGT) therapies to succeed, George White identifies several challenges to overcome. He says that […]

Ryan Leahy, a science communication expert in cell and gene therapy, at Phacilitate, says there is a lot to celebrate but also much to assess, question and challenge in this sector. While the global economic landscape faces a major crisis and biotech is not recession-proof, cell and gene therapy (CGT) has continued to progress with […]

The UK’s National Institute for Health and Care Excellence (NICE) has recommended additional uses for two CAR-T therapies from Gilead Sciences/Kite, as part of the Cancer Drugs Fund (CDF). Yescarta (axicabtagene ciloleucel: axi-cel) has been recommended by NICE for the treatment of eligible adult patients with diffuse large B cell lymphoma (DLBCL) and high-grade B-cell […]

The US Food and Drug Administration (FDA) has given the go-ahead to CytoAgents to initiate a US Phase Ib/IIa clinical trial investigating CTO1681 for cytokine release syndrome (CRS) in lymphoma patients receiving CAR-T cell therapy. This is an area of great unmet medical need as the majority of patients undergoing CAR-T treatment experience CRS and […]

Hosted by DDW and supported by BPS BioScience and AcroBiosystems, ‘Cancer immunotherapy – where will the future opportunities be?’ will be free to attend on May 10 at 8AM PST | 11AM EST | 4PM BST | 5PM CET.   Join this free webinar to learn about the biggest opportunities for the future of cancer immunotherapy.   […]

Hosted by DDW and supported by BPS BioScience and AcroBiosystems, ‘Cancer immunotherapy – where will the future opportunities be?’ will be free to attend on May 10 at 8AM PST | 11AM EST | 4PM BST | 5PM CET.   Join this free webinar to learn about the biggest opportunities for the future of cancer immunotherapy.   […]

University of California researchers have dosed the second participant in their clinical trial to identify a potential cure for HIV utilising CAR-T cell therapy. The first participant was dosed with anti-HIV duoCAR T cells at UC Davis Medical Center in mid-August. The trial is the first-in-human clinical study investigating the duo CAR-T cell therapy for […]

Hosted by DDW and supported by BPS BioScience and ACROBiosystems, ‘Cancer immunotherapy – where will the future opportunities be?’ will be free to attend on May 10 at 8AM PST | 11AM EST | 4PM BST | 5PM CET.   Join this free webinar to learn about the biggest opportunities for the future of cancer immunotherapy.   […]

Watch this free webinar to learn about the biggest opportunities for the future of cancer immunotherapy.   In this free webinar, you will hear from immunologist Dr Frédéric Triebel, CSO and CMO of Immutep, two experts from DeciBio: Dr Carl Schoellhammer, Principal, and Dr Joe Daccache, Senior Life Science Expert, Veronique Baron, Scientific Applications Manager, Marketing […]